- Home
- ATAI vs OSUR Comparison
ATAI vs OSUR Comparison
Compare ATAI & OSUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | OSUR |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 177.2M |
| IPO Year | 2021 | 1986 |
Fundamental Metrics
Financial Performance| Metric | ATAI | OSUR |
|---|---|---|
| Price | $4.14 | $2.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $14.00 | $3.00 |
| AVG Volume (30 Days) | ★ 3.6M | 834.3K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,018,000.00 | ★ $125,703,000.00 |
| Revenue This Year | $943.83 | N/A |
| Revenue Next Year | N/A | $3.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $2.08 |
| 52 Week High | $6.75 | $4.22 |
Technical Indicators
Market Signals| Indicator | ATAI | OSUR |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 49.34 |
| Support Level | $4.25 | $2.42 |
| Resistance Level | $4.63 | $2.65 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 52.91 | 52.38 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About OSUR OraSure Technologies Inc.
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.